Frontiers in Oncology (Apr 2024)
Corrigendum: Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study
- Mojtaba Azari,
- Mojtaba Azari,
- Maryam Barkhordar,
- Maryam Barkhordar,
- Tanaz Bahri,
- Tanaz Bahri,
- Soroush Rad,
- Soroush Rad,
- Hosein Kamranzadeh Fumani,
- Hosein Kamranzadeh Fumani,
- Seied Asadollah Mousavi,
- Seied Asadollah Mousavi,
- Sahar Tavakoli Shiraji,
- Sahar Tavakoli Shiraji,
- Morteza Azari,
- Morteza Azari,
- Parisa Shafaroudi,
- Parisa Shafaroudi,
- Mohammad Vaezi,
- Mohammad Vaezi
Affiliations
- Mojtaba Azari
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Mojtaba Azari
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Maryam Barkhordar
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Maryam Barkhordar
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Tanaz Bahri
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Tanaz Bahri
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Soroush Rad
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Soroush Rad
- Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Hosein Kamranzadeh Fumani
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Hosein Kamranzadeh Fumani
- Hematologic Malignancies Research Center, Tehran University of Medical Science, Tehran, Iran
- Seied Asadollah Mousavi
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Seied Asadollah Mousavi
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Sahar Tavakoli Shiraji
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Sahar Tavakoli Shiraji
- Hematologic Malignancies Research Center, Tehran University of Medical Science, Tehran, Iran
- Morteza Azari
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Morteza Azari
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Parisa Shafaroudi
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- Parisa Shafaroudi
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Mohammad Vaezi
- Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
- Mohammad Vaezi
- Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
- DOI
- https://doi.org/10.3389/fonc.2024.1397607
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords
- graft-versus-host disease (GVHD)
- hematopoietic stem cell transplantation (HSCT)
- donor parity
- overall survival
- relapse incidence